The Pediatric Home Health System Is Failing Children with Cancer

Key Takeaways

• Blinatumomab improves ALL survival, but home access limited.
• 70% of U.S. children lack pediatric home‑care services.
• Hospital stays cost >$5,000 daily, far exceeding home infusion savings.
• Low reimbursement and nurse shortage cripple pediatric home‑health capacity.
• Policy reform could extend Medicare “Hospital at Home” to children.

Summary

A landmark trial showed blinatumomab adds 10% survival for childhood acute lymphoblastic leukemia, yet most children cannot receive it at home. Roughly 70% lack access to pediatric home‑health services because reimbursement is low, nurses are scarce, and investment has lagged. Hospitalizing these patients costs over $5,000 per day, while home infusion could save about $30,000 per case. Experts urge Congress to fund a pediatric home‑infusion program, mirroring adult “Hospital at Home” initiatives.

Pulse Analysis

The introduction of blinatumomab marked a turning point in pediatric acute lymphoblastic leukemia therapy. Late‑2024 data showed a 10‑percentage‑point boost in survival and a two‑thirds drop in relapses when added to standard regimens. Unlike traditional chemotherapy, blinatumomab is delivered via a continuous 24‑hour infusion that avoids severe nausea or hair loss. Because the infusion can be managed safely outside a sterile ward, oncologists have long advocated for home‑based delivery, a model already proven in adult oncology and chronic disease care.

Despite the promise, the pediatric home‑health system is fragmented. Medicaid, the main payer, reimburses at rates too low to sustain specialized nursing teams, creating a nationwide shortage of pediatric‑trained home nurses. Many states lack any pediatric home‑care agencies, and recent budget cuts under the “One Big Beautiful Bill Act” threaten optional community‑based services. Meanwhile, Medicare’s “Hospital at Home” program has expanded rapidly for seniors, delivering comparable outcomes at lower cost. The disparity highlights a systemic bias that leaves children without the infrastructure to translate medical advances into real‑world benefit.

Closing the gap yields humanitarian and fiscal gains. A month‑long inpatient stay for blinatumomab can exceed six figures, while home‑infusion pathways have saved roughly $30,000 per patient in drug costs and freed critical beds. Recent bipartisan support for adult Hospital at Home creates a legislative opening to fund a pediatric home‑infusion demonstration program. Targeted federal matching, higher reimbursement, and training pipelines for pediatric home nurses could quickly expand capacity, especially in rural areas. Such reforms would ensure breakthroughs like blinatumomab reach every child, delivering care where it belongs—at home.